CTIS2023-506499-29-00招募中1 期
IGM-2323-101
IGM Biosciences Inc.0 个研究点目标入组 18 人开始时间: 2023年9月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid ArthritisMedDRA version: 21.0Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859Rheumatoid ArthritisCTIS2023-505127-31-00IGM Biosciences Inc.24
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55
进行中（未招募）
1 期
Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a single oral dose administration to healthy volunteers under fasting conditions in a crossover design.healthy volunteerCTIS2023-507599-34-00Geiser Pharma S.L.60
招募中
1 期
Study on the investigational drug IAMA-6, placebo-controlled, administered to healthy adult volunteers, at single oral doses and at multiple ascending oral doses to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of IAMA-6 and its interaction with foodCTIS2023-507454-33-00Iama Therapeutics S.r.l.72
进行中（未招募）
1 期
First administration in healthy volunteers of a single and increasing dose of a new molecule for the treatment of brain diseasesPost-Traumatic Stress Disorder (PTSD)MedDRA version: 21.1Level: PTClassification code: 10036316Term: Post-traumatic stress disorder Class: 100000004873CTIS2023-505030-99-00Rest Therapeutics36